Sugammadex is indicated for the rapid reversal of neuromuscular blockade induced by steroidal neuromuscular blocking agents such as rocuronium and vecuronium. Its key advantage is a unique and specific mechanism of action, encapsulating the neuromuscular blocker molecule and removing it from circulation, which leads to fast and predictable recovery of muscle function. Unlike traditional reversal agents, sugammadex works independently of acetylcholinesterase inhibition and does not require anticholinergic co-administration. This results in faster, more reliable reversal and improved safety, particularly in situations requiring immediate recovery, such as difficult airway management or high-risk patients. In anesthesia practice, sugammadex significantly enhances control, reduces residual paralysis risk, and supports safer postoperative outcomes.